Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 0 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

8
Corvus Pharmaceuticals (CRVS) Q2 2026: R&D Spend Doubles as Soqualitinib Pipeline Broadens
August 07, 2026
11
Corvus Pharmaceuticals (CRVS) Q4 2025: $189M Financing Extends Cash Runway to 2028 as Socalitinib Clinical Momentum Builds
March 13, 2026
9
Corvus Pharmaceuticals (CRVS) Q3 2025: R&D Spend Jumps 63% as Socolitinib Pipeline Momentum Builds
November 05, 2025
9
Corvus Pharmaceuticals (CRVS) Q2 2025: $35.7M Warrant Exercise Extends Cash Runway Into 2026
August 08, 2025
8
Corvus Pharmaceuticals (CRVS) Q1 2025: $31M Warrant Exercise Extends Cash Runway, Atopic Dermatitis Data Signals Pipeline Upside
July 05, 2025
9
Corvus Pharmaceuticals (CRVS) Q4 2024: Soquelitinib Advances with Broad Clinical Pipeline and $52M Cash Runway
March 25, 2025

Browse all companies